Quantcast

Latest Ken Alibek Stories

2011-09-28 09:43:20

High rates of parasitic infection in the region nearly 20 years after the collapse of the Soviet Union The open-access journal PLoS Neglected Tropical Diseases will publish an article emphasizing the rising burden of Neglected Tropical Diseases (NTDs) in Central Asia on Tuesday, Sept. 27th. According to the article's co-authors, Dr. Peter Hotez, President of the Sabin Vaccine Institute, and Dr. Ken Alibek of Nazarbayev University in Astana, Kazakhstan, the region continues to suffer from a...

ac6c5fb309fe6961f2be5a668298501c1
2010-06-23 10:56:05

The 2001 anthrax attacks in the United States are fostering development of a new generation of vaccines, antibiotics, and other medications to protect people against the potentially deadly bacteria in any future bioterrorist incident. That's the conclusion of a sweeping overview of scientific research on medical technology to combat the anthrax threat. It appears in ACS' bi-weekly Journal of Medicinal Chemistry. In the article, Dimitrios Bouzianas notes that several existing antibiotics are...

2010-05-18 12:53:08

Vaccinia immunization, as given to prevent the spread of smallpox, produces a five-fold reduction in HIV replication in the laboratory. Researchers writing in the open access journal BMC Immunology suggest that the end of smallpox vaccination in the mid-20th century may have caused a loss of protection that contributed to the rapid contemporary spread of HIV. Raymond Weinstein, a family doctor turned laboratory scientist at George Mason University, Manassas, Virginia, USA, worked with a team...

2009-09-30 07:00:00

CLEVELAND, Sept. 30 /PRNewswire/ -- Ganeden Biotech Inc., makers of the patented probiotic strain GanedenBC30® (Bacillus coagulans GBI-30, 6086), today announced two grants for early investigators. Grants focus on researching the effects of GanedenBC30 on human immune cells. Previous studies have demonstrated the ability of GanedenBC30 to modulate numerous human immune cells, both in vitro and in vivo. To be eligible, investigators must have a full-time faculty...

2009-09-03 07:54:00

ANNAPOLIS, Md., Sept. 3 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that data from the Company's third generation recombinant protective antigen (rPA) anthrax vaccine program and its Valortim((R)) anthrax anti-toxin program were presented at the Bacillus - ACT 2009 meeting, August 30 - September 3, 2009, organized by the American Society for Microbiology. David...

2008-10-09 09:00:52

Emergent BioSolutions Inc. (NYSE: EBS) announced today that two medical countermeasures included in its anthrax franchise -- BioThrax(R) (Anthrax Vaccine Adsorbed) and Anthrax Immune Globulin (AIG) -- have been included as covered countermeasures under the Public Readiness and Emergency Preparedness Act (PREP Act) pursuant to a declaration issued by the U.S. Department of Health and Human Services (HHS). In issuing this declaration, the Secretary of HHS determined that there is a credible...

2005-06-20 17:10:00

June 20, 2005 (La Jolla, CA). A collaborative team of scientists led by The Burnham Institute's Maurizio Pellecchia, Ph.D., has identified inhibitors of the anthrax toxin, termed lethal factor ("LF") that could be developed into an emergency treatment for exposure to inhalation anthrax. These findings will be published by the Proceedings of the National Academy of Sciences by Early Edition at the journal's website the week of June 20th. Bacillus anthracis ("anthrax") is a proven agent of...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related